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Diabetic retinopathy (DR) remains as the leading cause of blindness among working age individuals in developed countries.
Current treatments for DR (laser photocoagulation, intravitreal corticosteroids, intravitreal anti-VEGF agents, and vitreoretinal
surgery) are applicable only at advanced stages of the disease and are associated with signi�cant adverse effects. erefore, new
pharmacological treatments for the early stages of the disease are needed. Emerging evidence indicates that peroxisome proliferator-
activator receptors (PPARs) agonists (in particular PPAR𝛼𝛼) are useful for the treatment of DR. However, the underlying molecular
mechanisms are far from being elucidated. is paper mainly focuses on PPARs expression in the diabetic eye, its molecular
implications, and the effect of PPAR agonists as a new approach for the treatment of DR. e availability of this new strategy
will not only be bene�cial in treating DR but may also result in a shi� towards treating earlier stages of diabetic retinopathy, thus
easing the burden of this devastating disease (Cheung et al. (2010)).
1. Introduction
Diabetic retinopathy is the most common complication
of diabetes, and proliferative diabetic retinopathy (PDR)
remains the leading cause of blindness among working-age
individuals in developed countries [1]. Diabetic macular
edema (DME), another important event that occurs in
diabetic retinopathy, is more frequent in type 2 than type
1 diabetes [2]. Although PDR is the most common sight-
threatening lesion in type 1 diabetes, DME is the primary
cause of poor visual acuity in type 2 diabetes. Because of the
high prevalence of type 2 diabetes, DME is the main cause
of visual impairment for diabetic patients. In addition, DME
is almost invariably present when PDR is detected in type
2 diabetes [3]. Despite heterogeneity in patient selection
criteria, country and selection period, the prevalence of
patients with DR in Western countries is relatively similar,
ranging from 21.9 to 36.8% [4]. Population-based studies
suggest that about one-third of the diabetic population have
signs of DR and one-tenth have vision-threatening states
of retinopathy such as diabetic maculae edema (DME) and
proliferative diabetic retinopathy (PDR) [5, 6].
Neovascularization caused by severe hypoxia is the
hallmark of PDR, whereas vascular leakage caused by the
breakdown of the blood retinal barrier (BRB) is the main
event involved in the pathogenesis of DME.
Healthcare costs for patients with DR are almost double
than that of patients without it and they increase considerably
with the severity of DR [7, 8], which suggests that preventing
the progression of DRmay signi�cantly reduce the economic
burden related to this complication of diabetes [9].
Current treatments for DR (laser photocoagulation,
intravitreal corticosteroids, intravitreal anti-VEGF agents,
and vitreoretinal surgery) are applicable only at advanced
stages of the disease and are associated with signi�cant
adverse effects [10, 11]. erefore, new pharmacological
treatments for the early stages of the disease are needed.
In recent years, several experimental and clinical studies
have shown the bene�cial effects of peroxisome proliferator-
activator receptors (PPARs) agonists (in particular PPAR𝛼𝛼)
in diabetic retinopathy. However, the molecular mechanisms
are far from being elucidated. In this paper, we review PPARs
expression in the diabetic eye, its molecular implications,
2 PPAR Research
and the effect of PPAR agonists as a new approach for the
treatment of DR.
2. Peroxisome Proliferator-Activator
Receptors (PPARs) and Their Agonists:
A General Overview
Peroxisome proliferator-activator receptors (PPARs) are
members of the nuclear hormone receptor superfamily
of ligand-activated transcription factors that regulate gene
expression in response to nutritional and physiological stim-
uli.
e nuclear receptor superfamily can be divided into
two categories: �rst, the classic hormone receptors that bind
speci�c hormones (glucocorticoids, thyroid hormones, and
estrogen) and second, nuclear receptors that act as metabolic
sensors, binding to substrate or end-products of metabolic
pathways, such as the liver X receptors, the farnesoid X
receptor, hepatocyte nuclear factor 4𝛼𝛼, or PPARs [12].
PPARs were initially identi�ed as a peroxisome prolifer-
ator “binding-protein” capable of inducing hepatocyte per-
oxisome proliferation. Peroxisomes are subcellular organelles
whose main function is the removal of molecular oxygen
and breaking down hydrogen peroxide [13, 14]. However,
the peroxisomes are also involved in glycerolipid synthesis,
fatty-acid oxidation, glucose and cholesterol biosynthesis and
metabolism [15].
e PPARs function together with the retinoid X receptor
(RXR) is to regulate glucose and lipid metabolism. In the
presence of the speci�c ligands, the PPARs adopt an active
conformation by forming a heterodimer with the RXR,
resulting in binding to peroxisome proliferator response
elements in target genes, determining PPAR-dependent gene
expression [16]. A PPAR is a compact molecule, consisting of
5 or 6 structural regions (A–F) divided into four functional
domains. e C-domain of the PPARs is DNA-binding and
the E or F region is the ligand-binding site. e ligand-
binding site has a pivotal role in transcriptional activation
[15].
Despite the high levels of homologies at the protein level,
three isoforms have been identi�ed, each of which has dif-
ferent numbers of amin oacid residues: PAAR𝛼𝛼 (468 amino
acids residues), PAAR 𝛽𝛽/𝛿𝛿 (441 amino acids), and PPAR𝛾𝛾
(479 amino acids) [17].ey are distributed differently in the
body tissues and exert different functions.
PPAR𝛼𝛼 is highly expressed in tissues with elevated mito-
chondrial and peroxisomal fatty-acid beta-oxidation rates,
such as liver, heart muscle, kidney, skeletal muscle, brown
fat, and retina [18–20]. PPAR𝛼𝛼 is also present in monocytes,
macrophages, and endothelial cells [21].
PPAR 𝛽𝛽/𝛿𝛿 are distributed ubiquitously in almost all
tissues and recent data suggests their involvement in cell
proliferation, angiogenesis, and in�ammation [22]. PPAR𝛾𝛾
has been intensively studied for its crucial implication in glu-
cose homeostasis and insulin sensitivity [23]. PPAR𝛾𝛾 is also
involved in the regulation of lipid metabolism by increasing
the genes that regulate fatty-acid uptake and storage [24] and
plays a pivotal role in adipocyte differentiation and function
[25].
So far seven PPAR𝛾𝛾 isoforms have been identi�ed, most
of them (PPAR𝛾𝛾1, PPAR𝛾𝛾2, PPAR𝛾𝛾3, PPAR𝛾𝛾6, and PPAR𝛾𝛾7)
expressed abundantly in adipose tissue. PPAR𝛾𝛾4 and PPAR𝛾𝛾5
are expressed only in macrophages [23].
2.1. PPAR𝛼𝛼 Agonists. e �rst PPAR discovered was PPAR𝛼𝛼,
during the search of a molecular target for a group of
agents then referred to as peroxisome proliferators, as they
increased peroxisomal numbers in rodent liver tissue, apart
from improving insulin sensitivity. ese receptors, phar-
macologically related to the �brates, were discovered in
the early 1980s [26]. e main natural ligands of PPAR𝛼𝛼
are the fatty acids and endogenous eicosanoids. Physiolog-
ical concentrations of diet-derived unsaturated fatty acids
also activate PPAR𝛼𝛼 [19]. In addition, PPAR𝛼𝛼 are strongly
stimulated by synthetic molecules such as the �brates, a
class of amphipathic carboxylic acids (gem�brozile, clo�brate
and feno�brate). e main effects of PPAR𝛼𝛼-stimulation
in humans are decreasing triglycerides, shiing low-density
lipoprotein cholesterol to larger particles, and increasing
high-density lipoprotein cholesterol particles.
2.2. PPAR𝛾𝛾 Agonists. e main natural ligands of PPAR𝛾𝛾
are the fatty acids, the phospholipids and their oxidatively
modi�ed metabolites, and a group of natural nitroalkenes
[27]. One of the natural ligands of PPAR𝛾𝛾 is an oxidatively
modi�ed phospholipid, 15-deoxy-𝛿𝛿 12,14-prostaglandin J2
(15d-PGJ2) and there are also other J2 series prostaglandins.
In general, the endogenous ligands have a relatively low affin-
ity and show little speci�city towards the different PPARs.
Additionally, most of the effects of PGJ2 occur independent
of PPAR𝛾𝛾.
In 1995, a class of antidiabetic drugs, the thiazolidine-
diones (TZDs), were shown to activate PPAR𝛾𝛾 with high
affinity, even more effectively than any natural ligand [28].
Various synthetic ligands for PPAR𝛾𝛾 were developed, such
as the TZD family: ciglitazone, troglitazone, rosiglitazone,
and pioglitazone. Some non-TZD synthetic ligands such as
GW1929 and GW7845 are mainly used in experimental
research.
2.3. Dual 𝛼𝛼/𝛾𝛾 Agonists. In order to combine the bene�cial
effects of both PPAR𝛼𝛼 and PPAR𝛾𝛾 activation, dual 𝛼𝛼/𝛾𝛾
agonists have recently been developed. Synthetic molecules,
likemuraglitazar or tesaglitazar, were shown to be superior to
TZDs in terms of improving glucose metabolism and raising
HDL-c levels in T2D patients, but the phase III clinical trials
have been discontinued [29]. A meta-analysis of the phase
II and III clinical trials of muraglitazar revealed that it was
associated with a greater incidence of myocardial infarction,
stroke, transient ischemic attacks, and CHF when compared
to placebo or pioglitazone [30]. Tesaglitazar was generally
well tolerated but was associated with a greater increase
in serum creatinine level than placebo [31]. At present,
aleglitazar, a dual PPAR 𝛼𝛼/𝛾𝛾 agonist, currently in phase III
clinical development, seems to be a potent and balanced
activator of PPAR𝛼𝛼 and 𝛾𝛾, with bene�cial effects in type 2
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diabetic patients who have suffered a recent cardiovascular
event [32, 33].
Telmisartan, an angiotensin-II receptor (AT-1) blocker,
has been proven to be a dual PPAR 𝛿𝛿/𝛾𝛾 agonist, and beza�-
brate is a pan-PPAR agonist. Furthermore, telmisartan was
shown to have a bene�cial effect in a murine model of retinal
neovascularization, by promoting a dual AT-1 blockade and
PPAR𝛾𝛾 activation, suggesting a possible implication in the
treatment of DR [34, 35].
Several angiotensin-II receptor blockers (candesartan,
irbesartan, losartan, but not valsartan or olmesartan) were
shown to activate PPAR𝛾𝛾 ligands in vitro. However, only
telmisartan, and to a lesser extent candesartan, resulted in
signi�cant PPAR𝛾𝛾 agonism in cell cultures, but in vivo, sartan
treatment had no effect as insulin sensitizers [36] suggesting
a very weak PPAR𝛾𝛾 stimulation in vivo.
2.4. Dual 𝛼𝛼/𝛿𝛿Agonists. Molecules targeting both PPAR𝛼𝛼 and
PPAR𝛿𝛿 were also developed. GFT505 is a dual 𝛼𝛼/𝛿𝛿 agonist
currently completing a phase II clinical trial. It shows a good
tolerance and a signi�cant improvement of lipid and glucose
disorders associated with metabolic syndrome [37].
3. Distribution of the PPARs in the Retina
All of the PPARs are constitutively expressed in the whole
retina [38] but most of our knowledge refers to the retinal
pigment epithelia (RPE). It has recently been shown that
PPARs are expressed in cultures of primary RPE cells and
ARPE19 cells (a human immortalized line of RPE cells) [39].
Both cell types presented a lack of PPAR𝛾𝛾2 and moderate
PPAR𝛾𝛾1 and PPAR 𝛽𝛽/𝛿𝛿 expression. e ARPE-19 cells
showed a moderate expression of PPAR𝛼𝛼 while primary
RPE cells had a low representation. Interestingly, the same
study analyzed the PPARs in the freshly isolated RPE, and
the results were slightly different from the studies of cell
cultures: a lack of PPAR𝛾𝛾1 and PPAR𝛾𝛾2 expression and a high
representation of PPAR𝛼𝛼 and PPAR 𝛽𝛽/𝛿𝛿. However, the results
of the freshly isolated RPEmight have been altered due to the
small number and the signi�cant heterogeneity of the sample
and are in contrast to the �ndings of previous studies which
demonstrated the presence of PPAR𝛾𝛾 in the RPE [40]. ese
con�icting results suggest that further studies addressed to
evaluating the distribution of the PPARs not only in RPE, but
also in the neuroretina are needed.
4. Molecular Implications of PPAR𝛾𝛾 Activation
in Diabetic Retinopathy
PPAR𝛾𝛾 activation plays a key role in the development of DR.
In fact, several experimental studies have shown that PPAR𝛾𝛾
receptors are downregulated in the diabetic eye and that their
suppression is involved in the pathogenesis of DR [41, 42].
In addition, there is clinical evidence to suggest that some
PPAR𝛾𝛾 polymorphisms represent a genetic risk factor for
developing DR [43, 44].
PPAR𝛾𝛾 activationmight participate in abrogating the two
most important events that occur in DR: neurodegeneration
and microangioapathy.
4.1. Effect of PPAR𝛾𝛾 Activation in Retinal Neurodegeneration.
Although DR has been classically considered to be a micro-
circulatory disease of the retina, there is emerging evidence
to suggest that retinal neurodegeneration is an early event
in the pathogenesis of DR which antedates and participates
in the microcirculatory abnormalities that occur in DR [45,
46]. In this regard, it is worth mentioning that the main
features of retinal neurodegeneration (apoptosis and glial
activation) have been found in the retinas of diabetic donors
without any microcirculatory abnormalities appearing in
the ophthalmoscopic examinations performed during the
year before death [47, 48]. Retinal ganglions cells (RGCs),
located in the inner retina, are the retinal neurons in which
the apoptosis process related to diabetes is �rst detected
[49]. Regarding glial activation, it is important to note that
a complex milieu of dysregulated proin�ammatory factors
occurs in the diabetic retina, and while retinal microglia
and in�ltrating monocytic cells probably make an important
contribution, there is also strong evidence that Müller glia
shows in�ammation-linked responses when exposed to the
diabetic milieu [50, 51].
Glutamate, the major excitatory neurotransmitter in the
retina is an essential mediator of the retinal neurodegener-
ative process that occurs in DR. Glutamate has been found
elevated in the extracellular space in experimental models
of diabetes [52–55]. is extracellular and synaptic excess of
glutamate leads to the overactivation of the ionotropic glu-
tamate receptors, mainly alpha-amino-3-hydroxyl-5-methyl-
4-isoxazole-propionate (AMPA) andN-methyl-D-aspartame
(NMDA) receptors, which results in an uncontrolled intra-
cellular calcium response in postsynaptic neurons and cell
death [56, 57]. is deleterious effect of glutamate on retinal
neurons is known as “excitotoxicity” and retinal ganglion
cells are primarily affected.
Aoun et al. [58] demonstrated that two PPAR𝛾𝛾 ligands,
15d-PGJ2 and troglitazone protect RGC-5 (an established
transformed rat retinal ganglion cell line) against glutamate
insult. e neuroprotective effects of the two compounds
appeared to be mediated through an antioxidant rather than
a PPAR-gamma-dependent pathway. In addition, PPAR𝛾𝛾
is constitutively expressed in rat primary microglial cul-
tures and PPAR𝛾𝛾 activation had an anti-in�ammatory effect
[59, 60]. Furthermore, it has recently been demonstrated
that rosiglitazone attenuates diabetes-induced apoptosis in
retinal neurons of STZ-induced diabetic rats by inhibition
of phospho-STAT3 (p-STAT3) and cytokine signaling 3
(SOCS3) [61].
Apart from the neuroprotection due to the abrogation
of excitotoxicity, there is emerging evidence that PPAR𝛾𝛾
activation also inhibits the neurotoxicity resulting from the
overexpression of the renin-angiotensin system that exists in
DR [62–65].
Finally, activation of PPARgammamay play an important
role in regulating the expression of target genes that are
involved in lipid and fatty acidmetabolism in the photorecep-
tor renewal process.e RPE is a specialized epithelium lying
in the interface between the neural retina and the choriocap-
illaris where it forms the outer blood-retinal barrier (BRB).
However, the RPE is something more than a constituent of
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the BRB and the phagocytosis of shed photoreceptor mem-
branes is vitally important for maintaining the structural and
functional integrity of the retina [66]. In fact, photoreceptor
homeostasis is maintained mainly by the RPE’s phagocytic
capacity, which is able to degrade between 25.000 and 30.000
outer segment disks daily [67]. e RPE plays a central
role in the processing and recycling of fatty acids and other
lipids resulting from photoreceptor digestion. Ershov et al.,
using primary cultures from rat RPE cells, demonstrated
that photoreceptor phagocytosis selectively activates PPAR𝛾𝛾
expression while having no effect on PPAR𝛼𝛼 or PPAR
𝛽𝛽/𝛿𝛿 [67]. is result suggests the implication of PPAR𝛾𝛾
in preventing the possible deleterious effect of fatty acid
accumulation in the retina, thus conferring neuroprotection.
4.2. Effect of PPAR𝛾𝛾 Activation on Microangiopathy. Apart
from neuroprotection, PPAR𝛾𝛾 activation has bene�cial
effects on early microvascular abnormalities. e loss of per-
icytes and endothelial dysfunction are the hallmarks of these
early stages of diabetic microangiopathy, and the balance
between nitric oxide (NO) [vasodilator] and endothelin-
1 (ET-1) [vasoconstrictor] is essential in determining the
hemodynamic response of the capillaries. One of the most
important functional impairments in the early stages of DR
is the reduced production and bioavailability of NO [68] and
the increase of ET-1 [69]. A study focused on NO production
in pericytes showed that PPAR𝛾𝛾 is constitutively expressed
in the retinal pericytes and that troglitazone increased NO
production in a PPAR𝛾𝛾-dependent manner [70]. In addition,
it has been shown that pioglitazone elicits the endothelium-
dependent dilation of isolated porcine retinal arterioles
mediated byNO release [71]. Furthermore, PPAR𝛾𝛾 activation
inhibits ET-1 secretion from endothelial cells [72]. Taken
together, PPAR𝛾𝛾 activation exerts a clear bene�cial effect on
the imbalance between NO and ET-1 that exists in DR.
VEGF plays an essential role in the pathogenesis of DR
by leading to the disruption of the BRB (the main pathogenic
event in the development of DME) and by promoting neovas-
cularisation (the hallmark of PDR) [73]. erefore, the effect
of PPAR𝛾𝛾 agonists on VEGF plays a key role in accounting
for the clinical and experimental results of PPAR𝛾𝛾 agonists, in
particular TZDs in the development of both DME and PDR.
e relationship between TZDs and DME has generated
an intense debate that is still far from being elucidated.
Clinical evidence indicates that TZDs signi�cantly increase
the risk of heart failure by a PPAR𝛾𝛾-mediated mechanism
which leads to �uid retention. Because of this effect, there
has been concern about the possible relation between the
use of TZDs and DME. ere are several studies which
support this theory, especially in patients having impaired
renal function, cardiac failure, or associated insulin therapy
[74–78]. Fong and Contreras [77] in a large prospective
cohort study showed that TZDs users were more likely to
develop DME (OR, 2.6 [95% CI, 2.4–3.0]). Idris et al. [78],
in a retrospective cohort study of 103,368 patients with type
2 diabetes mellitus and without DME at baseline, showed at
1 year, an incidence of DME of 1.3% (𝑛𝑛 𝑛 𝑛𝑛) and 0.2%
(𝑛𝑛 𝑛 𝑛𝑛𝑛) among thiazolidinedione users (𝑛𝑛 𝑛 𝑛𝑛𝑛𝑛) and
nonusers (𝑛𝑛 𝑛 𝑛𝑛𝑛𝑛 𝑛𝑛𝑛), respectively. Aer Cox multiple
regression analysis, multiple imputation analysis to adjust
for missing values, and propensity score analysis to exclude
any selection bias, TZD use was associated with an increased
risk of DME at 1-year followup (OR, 2.3 [95% CI, 1.5–3.6])
and 10-year followup (HR, 2.3 [95% CI, 1.7–3.0]). e effect
was similar for pioglitazone and rosiglitazone. Combination
therapy with insulin plus TZD was associated with a higher
risk of DME aer propensity score adjustment (HR, 3.0 [95%
CI, 1.5–5.9]). By contrast in the ACCORD-eye substudy, no
association was observed between TZD exposure and DME
in patients with type 2 diabetes [79]. In this study, the cross-
sectional association of DME and visual acuity with TZD
was examined by means of baseline fundus photographs and
visual acuity measurements from the ACCORD trial. TZD
use was not associated with DME in unadjusted (odds ratio
[OR], 1.01; 95% con�dence interval [CI], 0.71–1.44; 𝑃𝑃 𝑛 𝑃𝑃𝑃)
and adjusted (OR, 0.97; 95%CI, 0.67–1.40; 𝑃𝑃 𝑛 𝑃𝑃𝑃) analyses.
In addition, TZD use was associated with slightly greater
visual acuity (0.79 letter; 95% CI, 0.20–1.38; 𝑃𝑃 𝑛 𝑃𝑛𝑛𝑃) but
this effect was of uncertain clinical signi�cance. Nevertheless,
it is worthy of mention that the ACCORD-EYE study had
an important selection bias because patients at potential risk
for macular edema were excluded [80]. ere is little exper-
imental information on the relationship between PPAR𝛾𝛾
activation and DME development. Muranaka et al. [81]
demonstrated that rosiglitazone was effective in protecting
against the breakdown of the BRB in streptozotocin-induced
diabetic rats but this effect was not mediated by VEGF down-
regulation. By contrast, Zheng at al. [82] have recently found
that simvastatin decreases retinal vascular permeability in
streptozotocin-induced diabetic rats through the inhibition
of VEGF expression and p38MPAK activity mediated by the
PGC-1𝛼𝛼. It was demonstrated that PPAR𝛾𝛾 activation by PIO
upregulates PGC-1𝛼𝛼 suggesting a protective effect of [83]
PPAR𝛾𝛾 activation on the breakdown of the BRB induced
by diabetes. Taken together, current evidence regarding the
relationship between PPAR𝛾𝛾 activation and BRB function
is confusing and further clinical and experimental studies
addressed to examining this issue are urgently required.
e role of PPAR𝛾𝛾 activation in VEGF-induced PDR is
also worthy of discussion. Several studies showed a proangio-
genic effect of PPAR𝛾𝛾 activation by the increased expression
of VEGF, suggesting a possible deleterious effect in PDR [84–
86]. However, these studies were performed in human vas-
cular muscle cell [84], adipocytes [85], and cultured cardiac
myo�broblasts [86]. e heterogeneity of the behaviour of
endothelial cells in several body compartments is well known.
erefore, the results obtained from a certain cell type cannot
be extrapolated to another. In the retina, it seems that PPAR𝛾𝛾
activation has an antiangiogenic effect. Murata et al. [87]
using the oxygen-induced ischemia (OII) mouse model of
retinal neovascularization showed that PPAR𝛾𝛾 activation by
intravitreous administration of troglitazone or rosiglitazone
inhibited VEGF-mediated neovascularisation. Interestingly,
VEGF was not signi�cantly inhibited in the ganglion cell
layer, thus preserving the neuroprotective properties of
VEGF in this critical neural layer. Aljada et al. [88] demon-
strated by using chick chorioallantoic membrane (CAM)
model that rosiglitazone and pioglitazone inhibited the
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proangiogenic effects of bFGF (basic �broblast growth factor)
and VEGF. Higuchi et al. [89] found that pioglitazone atten-
uated pathological retinal microvessel formation in a mouse
model of OII through adiponectin-mediated modulation of
TNF𝛼𝛼 production. More recently, Rodrigues et al. [90] using
ARPE-19 cell cultures demonstrated that PPAR𝛾𝛾 agonists can
have differential effects on RPE survival in response to oxida-
tive stress: troglitazone but not rosiglitazone or pioglitazone
was able to improve the RPE response to oxidative stress by
downregulating VEGF expression. Finally, Hatanaka et al.
[91], have shown that pioglitazone inhibits �brotic change in
primary monkey RPECs through the suppression of TGF-𝛽𝛽
signaling. A clinical study which supports these experimental
�ndings was conducted by Shen et al., [92] who showed in a
case-control study that rosiglitazone reduced the progression
from NPDR to PDR over 3 years by 59%.
Apart from the potential bene�cial effects on neurode-
generation and microvascular abnormalities, PPAR𝛾𝛾 activa-
tion might also counteract other mechanisms involved in the
pathogenesis of DR such as in�ammation and leukostasis
[81, 93, 94], the overexpression of matrix metalloproteinases
[95] or the increase in platelet aggregation [96].
5. Molecular Implications of the PPAR𝛼𝛼 in
Diabetic Retinopathy
Ever since 1969 there has been clinical evidence of a bene�cial
effect of PPAR𝛼𝛼 activation on diabetic retinopathy. Harrold
et al. showed an improvement in retinal exudate aer 1 year
of treatment with clo�brate, without signi�cant effects on
other retinal lesions [97]. e data was con�rmed by Dorne
in 1977, who suggested clo�brate as the treatment of choice
for exudative diabetic retinopathy [98].
e current evidence that PPAR𝛼𝛼 activation has a ben-
e�cial effect in DR comes from two seminal clinical trials:
the FIELD [99, 100] and the ACCORD-Eye [101] studies
which showed that DR progression was signi�cantly reduced
by feno�brate (a PPAR𝛼𝛼 used as a hypolipemiant agent).
e FIELD Study raised the prospect of the prevention
of DR via treatment with feno�brate. FIELD was essen-
tially a cardiovascular trial, with a large population (𝑛𝑛 𝑛
9795) of type 2 diabetes patients without statin treatment
at baseline randomised to receive feno�brate or placebo for
5 years [99]. Primary and secondary endpoints focussed on
cardiovascular events. Eight per cent of the population of
FIELD had retinopathy at baseline, and the need for laser
photocoagulation for retinopathy was included among the a
priori tertiary endpoints of the trial [99]. Feno�brate reduced
the incidence of patients requiring laser photocoagulation
(from 5.2% on placebo to 3.6%, 𝑃𝑃 𝑛 𝑃𝑃𝑃𝑃𝑃𝑃). ere
was greater absolute bene�t in patients with, rather than
without, pre-existing retinopathy [100]. However, baseline
photographic assessment of retinal status was only made in
10% of patients. Moreover, the criteria for the use of laser
treatment were not pre-speci�ed and therefore are likely to
have been heterogeneous [102].
A substudy conducted in 1012 patients explored the
effects on retinopathy outcomes in the FIELD study in more
detail [100]. In this ophthalmological substudy, retinopa-
thy status and severity were assessed from two-�eld 45∘
colour fundus photographs of the macula (stereoscopic)
and a disc/nasal �eld taken at baseline, 2 years and 5
years, and graded with Early Treatment Diabetic Retinopathy
Study (ETDRS) criteria. A marked and signi�cant reduction
(∼70%) in the risk of laser treatment for retinopathy was
again demonstrated for feno�brate versus placebo. However,
only 28 patients required laser treatment (23 in the placebo
group and 5 in the feno�brate group). In addition, DR pro-
gression, (2-step Early TreatmentDiabetic Retinopathy Study
[ETDRS] scale, the primary endpoint), was signi�cantly
reduced with feno�brate in those patients with preexisting
DR at baseline (from 14.6% to 3.1%, 𝑃𝑃 𝑛 𝑃𝑃𝑃𝑃𝑃), but not in
those without DR at baseline. However, the number of events
was small (14 in the placebo group and 3 in the feno�brate
group).
e ACCORD trial included a lipid arm, in which
patients were randomly assigned to treatment with feno�-
brate or placebo in addition to open-label simvastatin [103].
Patients eligible for this arm were also enrolled in the
glycemia evaluation, but met additional recruitment criteria
relating to lipids (LDL cholesterol 1.55–4.65mmol/L, HDL
cholesterol <1.29mmol/L [<1.42mmol/L for women], and
triglycerides <8.5mmol/L [<4.5mmol/L if receiving lipid-
modifying therapy]). Retinopathy outcomes in ACCORD
were evaluated in a 4-year eye substudy [101]. Randomiza-
tion to feno�brate relative to placebo (on background therapy
with simvastatin) was associated with a signi�cant decrease
(from 10.2% to 6.5%, 𝑃𝑃 𝑛 𝑃𝑃𝑃𝑃𝑃) in DR progression (3 or
more steps on the EDTRS), with greater effect in patients with
evidence of DR at baseline (absolute RR 6.9% versus 0.2%
in those without DR at baseline). It should be noted that the
reduction obtained with feno�brate plus simvastatin (−40%;
𝑃𝑃 𝑛 𝑃𝑃𝑃𝑃𝑃) was even higher than that obtained in the arm of
intensive glycaemic control (−33%; 𝑃𝑃 𝑛 𝑃𝑃𝑃𝑃𝑃).
e similarities between the effects of feno�brate on
outcomes in the eye between the FIELD and ACCORD-
EYE studies are striking. In both trials, randomization to
feno�brate (in combination with a statin in a substantial
proportion of patients by study end in FIELD, and exclusively
with a statin in ACCORD-EYE) led to statistically and clin-
ically signi�cant reductions in the risk of a range of clinical
endpoints related to retinopathy [99–101]. In summary, these
trial data show that feno�brate treatment provides a relative
reduction in DR progression of 30–40% over 4 to 6 years,
with greater bene�t in patients with pre-existing DR. ese
bene�ts were achieved despite a lack of signi�cant reductions
in the risk of the primary composite cardiovascular endpoint
in either study (although there was a signi�cant reduction in
total cardiovascular events in FIELD) [99, 103].
5.1. Mechanisms o� �ction o� �eno��rate
5.1.1. Lipid-Mediated Mechanisms. Feno�brate is indicated
for the treatment of hypertriglyceridemia and mixed dis-
lipidemia. Its main action is to lower plasma triglyceride
levels, but it also reduces total and LDL cholesterol, raises
HDL cholesterol, and decreases the concentration of small
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LDL cholesterol particles and apolipoprotein B. In the
FIELD study, there was essentially no change in HDL-
cholesterol with feno�brate (mean reduction of 0.01mmol/L
for feno�brate versus placebo at study end) and only a mod-
est change in triglycerides (mean reduction 0.24mmol/L)
[99]. In ACCORD, mean HDL-cholesterol increased from
0.98mmol/L to 1.07mmol/L with feno�brate and from
0.99mmol/L to 1.05mmol/L with placebo [103]. Similarly,
baseline and �nal triglyceride levels were 1.85mmol/L and
1.38mmol/L in the feno�brate group of the ACCORD lipid
arm, compared with 1.81mmol/L and 1.63mmol/L in the
placebo group. erefore, it seems that the bene�cial effects
of feno�brate on diabetic retinopathy are unrelated to quan-
titative changes of serum lipids. However, it is not known
whether the effectiveness of feno�brate in modulating the
qualitative properties of lipoproteins (i.e., reducing remnants
and small dense LDL particles) can contribute to its bene�cial
effects.
It should also be noted that the mechanisms regulating
intraretinal lipid transport, rather than serum lipid levels,
might be more important in the pathogenesis of DR [102]. In
this regard, we have recently shown that apolipoprotein A1
(apo-A1) is overexpressed in the retina of diabetic patients
[104, 105]. Apo-A1 is a key factor for the intraretinal
transport of lipids, thus preventing lipid deposition and
lipotoxicity, and is also a potent scavenger of reactive oxygen
species. erefore, apo-A1 could play an important role in
protecting the retina from oxidative stress. ese �ndings
have led us to hypothesize that the retinas of diabetic patients
have a higher content of apo-A1 as a protective mechanism
and, consequently, that those patients with less capacity for
apo-A1 production by the retina will be more prone to
develop lipid deposition (hard exudates) and retinal damage
induced by oxidative stress. Feno�bric acid has been shown to
enhance transcription of the apoA-1 gene in the liver [106],
macrophages, and �broblasts [107], but whether this is also
true at the retinal level remains to be elucidated.
Finally, it has recently been shown that circulating apoAI
may be an independent protective factor for the development
of DR [108]. erefore it is possible that the increase in
apoAI plasma levels induced by feno�brate participates in its
bene�cial action on DR.
5.1.2. Nonlipidic-Mediated Mechanisms. ere are several
nonlipidic mechanisms by which feno�brate, or its active
metabolite, feno�bric acid (FA) can exert bene�cial effects in
preventing or arresting DR.
5.2. Neuroprotective Effect. As previously mentioned, neu-
rodegeneration plays an essential role in the pathogenesis
of DR. In experimental models of cerebral ischaemia and
neurodegenerative diseases, PPAR𝛼𝛼 activation had a neu-
roprotective effect, independent of lipid metabolism [109].
Antioxidant, anti-in�ammatory, and antiapoptotic properties
of feno�brate have been implicated in this effect.
5.3. Improvement in Endothelial Function and Anti-Apoptotic
Activity. FA exerts a protective effect on the microvascula-
ture by suppressing apoptosis and stimulating nitric oxide
synthase (eNOS) phosphorylation and NO production. is
is mediated by AMPK activation, as has been shown by
studies of numerous cell systems, including human retinal
endothelial cells [110–113].is effect is unrelated to PPAR𝛼𝛼
activation, as is evident in human retinal endothelial cells
[113]. In addition, a recent study showed that FA elicits
dual protective effects in the RPE by the down-regulation
of stress-mediated signalling and the induction of autophagy
and survival pathways [114].
5.�. Antio�idant and Anti-In�ammatory Activity. Feno�brate
may mitigate the adverse effects of oxidative and in�am-
matory stress, which are involved in the development of
DR. It has been reported that PPAR𝛼𝛼 activation induces the
expression and activation of antioxidant enzymes, such as
superoxide dismutase and glutathione peroxidase [109], thus
ameliorating oxidative stress, a key factor for the develop-
ment of DR [115].
PPAR𝛼𝛼 activation induces the apoptosis of human
monocyte-derived macrophages [116] and inhibits the
expression of vascular cell adhesion molecules on the
endothelium [117]. ese effects might be potentially rele-
vant in preventing leukostasis. Furthermore, it has recently
been shown that FA prevents the deleterious action of IL-
1𝛽𝛽 in the disruption of the BRB, thus supporting the role
of proin�ammatory cytokines in the pathogenesis of DME
[118].
5.5. Preventive Effects on Blood-Retinal Barrier Breakdown.
e breakdown of the BRB, due to the disruption of
tight junctions with subsequent leakage, is the main factor
implicated in DME. Feno�brate prevents DME progression,
suggesting a possible effect in reducing the permeability
associated with DR. In cultures of human RPE cells (which
constitute the external BRB), FA prevented the disorgan-
isation of tight junction proteins and hyperpermeability
provoked by the diabeticmilieu.is ismediated by the effect
of FA in reducing interleukin-𝛽𝛽-induced AMPK activation
[118]. Finally, it has recently been shown that FA down-
regulates the overexpression of basement membrane com-
ponents (�bronectin and collagen IV) in RPE cells cultured
in conditions mimicking the diabetic milieu. Exposure to
FA reduced the increase in permeability associated with the
overexpression of �bronectin and collagen IV in a dose-
dependent manner [119].
5.6. Antiangiogenic Activity. PPAR-𝛼𝛼 is present in endothelial
cells [120], and its activation by means of PPAR-𝛼𝛼 agonists
has recently been shown to inhibit expression of VEGF
receptor 2 (VEGFR2) and neovascularization in human
umbilical endothelial cells [121]. Varet et al. [122] have
demonstrated that feno�brate inhibits angiogenesis in vitro
and in vivo as well as basic �broblast growth factor-induced
angiogenesis in vivo. In addition, in cells derived from
human ovarian cancer, clo�bric acid (a PPAR-𝛼𝛼 agonist)
downregulates VEGF expression [123]. Finally. Chen et al.
[124] have recently shown that both oral and intravitreal
administration of feno�brate ameliorated leukostasis and
retinal vascular leakage in type 1 murine models, and
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that they also attenuated the overexpression of adhesion
molecules and VEGF. e bene�cial effects of feno�brate
were blocked by a speci�c PPAR𝛼𝛼 antagonist, thus suggesting
a PPAR𝛼𝛼-dependent mechanism.
6. Molecular Implications of the PPAR 𝛽𝛽/ 𝛿𝛿 in
Diabetic Retinopathy
PPAR𝛽𝛽/𝛿𝛿 is also expressed in the retina. Little is known about
the effects of PPAR 𝛽𝛽/𝛿𝛿 in the eye and less about its effects in
the diabetic eye. Most of the studies have associated PPAR
𝛽𝛽/𝛿𝛿 activation with proangiogenic and proin�ammatory
effects. e PPAR 𝛽𝛽/𝛿𝛿 agonist GW501516 stimulates human
umbilical vein endothelial cells proliferation and increased
VEGF expression [125].
7. Conclusions
Improvements in diabetes care and management have been
crucial in lowering the incidence and severity of DR. Nev-
ertheless, DR remains the most common cause of vision
impairment in working age adults in the US and Europe and
retinal neovascularization occurs in up to 20% of patients
with diabetes. As greater knowledge of the molecular mecha-
nisms involved in the pathogenesis of DR has been obtained,
new therapeutic products have been developed. In this
regard, scienti�c evidence has accumulated in recent years
regarding the role of PPAR activation in the pathogenesis
of DR. As far as we know, PPAR𝛾𝛾 activation would appear
to have a bene�cial effect in the early stages of DR. e
bene�cial effects of PPAR𝛼𝛼 activation by feno�brate in DR
have been demonstrated in two large clinical trials (FIELD
and ACCORD-EYE� with greater bene�t in patients with
pre-existing DR. By contrast, PPAR 𝛽𝛽/𝛿𝛿 activation has a
deleterious effect, promoting in�ammation and angiogenesis.
However, the underlying mechanisms by which PPARs are
exerting their effects in the retina are only just beginning to
be understood.
Concerted efforts to better de�ne the presence and distri-
bution of PPARs in freshly isolated human retina and speci�c
studies addressed to examining the mechanistic pathways
and functional effects involved in PPAR activation in both
nondiabetic and diabetic retina are urgently needed.
Finally, improved understanding of the mechanisms of
action of PPARs will facilitate their clinical application.
Ophthalmologists and physicians treating diabetic patients
should be aware of the potential usefulness of PPARs and
work together not only in future research, but also in
establishing clinical guidelines that will include these drugs
as medical treatments for DR. Only such coordinated action,
together with rational strategies targeting prevention, will be
effective in reducing the burden of DR and improving clinical
outcomes related to this devastating complication of diabetes.
References
[1] N. Cheung, P. Mitchell, and T. Y. Wong, “Diabetic retinopathy,”
e Lancet, vol. 376, no. 9735, pp. 124–136, 2010.
[2] R. Klein, S. E. Moss, B. E. K. Klein, M. D. Davis, and D. L.
DeMets, “Wisconsin epidemiologic study of diabetic retinopa-
thy. XII. Relationship of C-peptide and diabetic retinopathy,”
Diabetes, vol. 39, no. 11, pp. 1445–1450, 1990.
[3] L. Tong, S. A. Vernon, W. Kiel, V. Sung, and G. M. Orr, “Associ-
ation of macular involvement with proliferative retinopathy in
type 2 diabetes,” Diabetic Medicine, vol. 18, no. 5, pp. 388–394,
2001.
[4] C. Delcourt, P. Massin, and M. Rosilio, “Epidemiology of dia-
betic retinopathy: expected vs reported prevalence of cases in
the French population,”Diabetes andMetabolism, vol. 35, no. 6,
pp. 431–438, 2009.
[5] E. Chen, M. Looman, M. Laouri et al., “Burden of illness of
diabetic macular edema: literature review,” Current Medical
Research and Opinion, vol. 26, no. 7, pp. 1587–1597, 2010.
[6] E. L. Lamoureux and T. Y.Wong, “Diabetic retinopathy in 2011:
further insights from new epidemiological studies and clinical
trials,” Diabetes Care, vol. 34, no. 4, pp. 1066–1067, 2011.
[7] L. J. Lee, A. P. Yu, K. E. Cahill et al., “Direct and indirect
costs among employees with diabetic retinopathy in the United
States,”CurrentMedical Research and Opinion, vol. 24, no. 5, pp.
1549–1559, 2008.
[8] E.M. Pelletier, B. Shim, R. Ben-Joseph, and J. J. Caro, “Econom-
ic outcomes associated with microvascular complications of
type 2 diabetes mellitus: results from a US claims data analysis,”
Pharmacoeconomics, vol. 27, no. 6, pp. 479–490, 2009.
[9] E. Heintz, A. B. Wirehn, B. B. Peebo, U. Rosenqvist, and L. A.
Levin, “Prevalence and healthcare costs of diabetic retinopathy:
a population-based register study in Sweden,”Diabetologia, vol.
53, no. 10, pp. 2147–2154, 2010.
[10] Q. Mohamed, M. C. Gillies, and T. Y. Wong, “Management of
diabetic retinopathy: a systematic review,” e Journal of the
American Medical Association, vol. 298, no. 8, pp. 902–916,
2007.
[11] R. Simó and C. Hernández, “Advances in the medical treatment
of diabetic retinopathy,” Diabetes Care, vol. 32, no. 8, pp.
1556–1562, 2009.
[12] M. C. Sugden, P. W. Caton, and M. J. Holness, “PPAR control:
it’s SIRTainly as easy as PGC,” Journal of Endocrinology, vol. 204,
no. 2, pp. 93–104, 2010.
[13] N. D. Lalwani, K. Alvares, and M. K. Reddy, “Peroxisome
proliferator-binding protein: identi�cation and partial char-
acterization of nafenopin-, clo�bric acid-, and cipro�brate-
binding proteins from rat liver,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 84, no.
15, pp. 5242–5246, 1987.
[14] N. D. Lalwani, W. E. Fahl, and J. K. Reddy, “Detection of a
nafenopin binding protein in rat liver cytosol associated with
the induction of peroxisome proliferation by hypolipidemic
compounds,” Biochemical and Biophysical Research Communi-
cations, vol. 116, no. 2, pp. 388–393, 1983.
[15] J. Vamecq and N. Latruffe, “Medical signi�cance of peroxisome
proliferator-activated receptors,”e Lancet, vol. 354, no. 9173,
pp. 141–148, 1999.
[16] R. M. Evans, “e steroid and thyroid hormone receptor super-
family,” Science, vol. 240, no. 4854, pp. 889–895, 1988.
[17] L. Fajas, D. Auboeuf, E. Raspé et al., “e organization,
promoter analysis, and expression of the human PPAR𝛾𝛾 gene,”
e Journal of Biological Chemistry, vol. 272, no. 30, pp.
18779–18789, 1997.
8 PPAR Research
[18] O. Braissant, F. Foufelle, C. Scotto, M. Dauça, and W. Wahli,
“Differential expression of peroxisome proliferator-activated
receptors (PPARs): tissue distribution of PPAR-𝛼𝛼, -𝛽𝛽, and -𝛾𝛾 in
the adult rat,” Endocrinology, vol. 137, no. 1, pp. 354–366, 1996.
[19] D. Auboeuf, J. Rieusset, L. Fajas et al., “Tissue distribution
and quanti�cation of the expression of mRNAs of peroxi-
some proliferator-activated receptors and liver X receptor-𝛼𝛼 in
humans: no alteration in adipose tissue of obese and NIDDM
patients,” Diabetes, vol. 46, no. 8, pp. 1319–1327, 1997.
[20] T. Lemberger, O. Braissant, C. Juge-Aubry et al., “PPAR tissue
distribution and interactions with other hormone-signaling
pathways,”Annals of the New York Academy of Sciences, vol. 804,
pp. 231–251, 1996.
[21] M. del V. Cano and P. L. Gehlbach, “PPAR-𝛼𝛼 ligands as potential
therapeutic agents for wet age-related macular degeneration,”
PPAR Research, vol. 2008, Article ID 821592, 5 pages, 2008.
[22] D. Bishop-Bailey, “PPARs and angiogenesis,” Biochemical Soci-
ety Transactions, vol. 39, pp. 1601–1605, 2011.
[23] J. Zhou, K. M. Wilson, and J. D. Medh, “Genetic analysis of
four novel peroxisome proliferator activated receptor-𝛾𝛾 splice
variants in monkey macrophages,” Biochemical and Biophysical
Research Communications, vol. 293, no. 1, pp. 274–283, 2002.
[24] G. Ding, M. Fu, Q. Qin et al., “Cardiac peroxisome proliferator-
activated receptor 𝛾𝛾 is essential in protecting cardiomyocytes
from oxidative damage,” Cardiovascular Research, vol. 76, no.
2, pp. 269–279, 2007.
[25] A. W. Norris, L. Chen, S. J. Fisher et al., “Muscle-speci�c
PPAR𝛾𝛾-de�cient mice develop increased adiposity and insulin
resistance but respond to thiazolidinediones,” e Journal of
Clinical Investigation, vol. 112, no. 4, pp. 608–618, 2003.
[26] I. Issemann and S. Green, “Activation of amember of the steroid
hormone receptor superfamily by peroxisome proliferators,”
Nature, vol. 347, no. 6294, pp. 645–650, 1990.
[27] B. Desvergne and W. Wahli, “Peroxisome proliferator-activated
receptors: nuclear control of metabolism,” Endocrine Reviews,
vol. 20, no. 5, pp. 649–688, 1999.
[28] D. M. Kendall, C. J. Rubin, P. Mohideen et al., “Improvement of
glycemic control, triglycerides, and HDL cholesterol levels with
muraglitazar, a dual (𝛼𝛼/𝛾𝛾) peroxisome proliferator-activated
receptor activator, in patients with type 2 diabetes inadequately
controlled with metformin monotherapy: a double-blind, ran-
domized, pioglitazone-comparative study,” Diabetes Care, vol.
29, no. 5, pp. 1016–1023, 2006.
[29] C. V. Rizos, M. S. Elisaf, D. P. Mikhailidis, and E. N. Liberopou-
los, “How safe is the use of thiazolidinediones in clinical
practice?” Expert Opinion on Drug Safety, vol. 8, no. 1, pp.
15–32, 2009.
[30] S. E. Nissen, K. Wolski, and E. J. Topol, “Effect of muraglitazar
on death and major adverse cardiovascular events in patients
with type 2 diabetes mellitus,” e Journal of the American
Medical Association, vol. 294, no. 20, pp. 2581–2586, 2005.
[31] R. E. Ratner, S. Parikh, and C. Tou, “Efficacy, safety and
tolerability of tesaglitazar when added to the therapeutic reg-
imen of poorly controlled insulin-treated patients with type 2
diabetes,” Diabetes and Vascular Disease Research, vol. 4, no. 3,
pp. 214–221, 2007.
[32] M. Dietz, P. Mohr, B. Kuhn et al., “Comparative molecular
pro�ling of the PPARalpha/gamma activator aleglitazar: PPAR
selectivity, activity and interaction with cofactors,” ChemMed-
Chem, vol. 7, no. 6, pp. 1101–1111, 2012.
[33] M. A. Cavender and A. M. Lincoff, “erapeutic potential
of aleglitazar, a new dual PPAR-alpha/gamma agonist: impli-
cations for cardiovascular disease in patients with diabetes
mellitus,”American Journal of Cardiovascular Drugs, vol. 10, no.
4, pp. 209–216, 2010.
[34] H. A. Pershadsingh and D. M. Moore, “PPAR𝛾𝛾 agonists:
potential as therapeutics for neovascular retinopathies,” PPAR
Research, vol. 2008, Article ID 164273, 13 pages, 2008.
[35] I. Imayama, T. Ichiki, K. Inanaga et al., “Telmisartan down-
regulates angiotensin II type 1 receptor through activation of
peroxisome proliferator-activated receptor 𝛾𝛾,” Cardiovascular
Research, vol. 72, no. 1, pp. 184–190, 2006.
[36] D. V. Erbe, K. Gartrell, Y. L. Zhang et al., “Molecular activation
of PPAR𝛾𝛾 by angiotensin II type 1-receptor antagonists,”Vascu-
lar Pharmacology, vol. 45, no. 3, pp. 154–162, 2006.
[37] B. Cariou, Y. Zair, B. Staels, and E. Bruckert, “Effects of the new
dual PPAR alpha/delta agonist GFT505 on lipid and glucose
homeostasis in abdominally obese patients with combined
dyslipidemia or impaired glucose metabolism,” Diabetes Care,
vol. 34, no. 9, pp. 2008–2014, 2011.
[38] A. A. Herzlich, X. Ding, D. Shen, R. J. Ross, J. Tuo, and C. C.
Chan, “Peroxisome proliferator-activated receptor expression
inmurinemodels and humans with age-relatedmacular degen-
eration,” e Open Biology Journal, vol. 2, pp. 141–148, 2009.
[39] M. A. Dwyer, D. Kazmin, P. Hu, D. P. McDonnell, and G.
Malek, “Research resource: nuclear receptor atlas of human
retinal pigment epithelial cells: potential relevance to age-
related macular degeneration,” Molecular Endocrinology, vol.
25, no. 2, pp. 360–372, 2011.
[40] S. Qin, A. P. McLaughlin, and G. W. De Vries, “Protection
of RPE cells from oxidative injury by 15-deoxy-Δ 12,14-
prostaglandin J2 by augmenting GSH and activating MAPK,”
Investigative Ophthalmology &Visual Science, vol. 47, no. 11, pp.
5098–5105, 2006.
[41] F. Wang, L. Gao, B. Gong et al., “Tissue-speci�c expression of
PPAR mRNAs in diabetic rats and divergent effects of cilosta-
zol,” Canadian Journal of Physiology and Pharmacology, vol. 86,
no. 7, pp. 465–471, 2008.
[42] A. Taw�k, T. Sanders, K. Kahook, S. Akeel, A. Elmarakby, and
M. Al-Shabrawey, “Suppression of retinal peroxisome prolifer-
ator-activated receptor 𝛾𝛾 in experimental diabetes and oxygen-
induced retinopathy: role of NADPH oxidase,” Investigative
Ophthalmology & Visual Science, vol. 50, no. 2, pp. 878–884,
2009.
[43] V. Costa, A. Casamassimi, K. Esposito et al., “Characterization
of a novel polymorphism in PPARG regulatory region asso-
ciated with type 2 diabetes and diabetic retinopathy in Italy,”
Journal of Biomedicine and Biotechnology, vol. 2009, Article ID
126917, 7 pages, 2009.
[44] M. G. Petrovič, T. Kunej, B. Peterlin, P. Dovč, and D. Petro-
vič, “Gly482Ser polymorphism of the peroxisome proliferator-
activated receptor-𝛾𝛾 coactivator-1 genemight be a risk factor for
diabetic retinopathy in Slovene population (Caucasians) with
type 2 diabetes and the Pro12Ala polymorphism of the PPAR𝛾𝛾
gene is not,”Diabetes/Metabolism Research and Reviews, vol. 21,
no. 5, pp. 470–474, 2005.
[45] C. Hernandez and R. Simo, “Neuroprotection in diabetic reti-
nopathy,” Current Diabetes Reports, vol. 12, no. 4, pp. 329–337,
2012.
[46] R. Simo and C. Hernandez, “Neurodegeneration is an early
event in diabetic retinopathy: therapeutic implications,” British
Journal of Ophthalmology, vol. 96, no. 10, pp. 1285–1290, 2012.
PPAR Research 9
[47] E. Carrasco, C. Hernández, A.Miralles, P. Huguet, J. Farrés, and
R. Simó, “Lower somatostatin expression is an early event in
diabetic retinopathy and is associated with retinal neurodegen-
eration,” Diabetes Care, vol. 30, no. 11, pp. 2902–2908, 2007.
[48] M. Garcia-Ramírez, C. Hernández, M. Villarroel et al., “Inter-
photoreceptor retinoid-binding protein (IRBP) is downregu-
lated at early stages of diabetic retinopathy,” Diabetologia, vol.
52, no. 12, pp. 2633–2641, 2009.
[49] H. W. van Dijk, F. D. Verbraak, P. H. B. Kok et al., “Decreased
retinal ganglion cell layer thickness in patients with type 1
diabetes,” Investigative Ophthalmology & Visual Science, vol. 51,
no. 7, pp. 3660–3665, 2010.
[50] E. Rungger-Brändle, A. A. Dosso, and P. M. Leuenberger, “Glial
reactivity, an early feature of diabetic retinopathy,” Investigative
Ophthalmology & Visual Science, vol. 41, no. 7, pp. 1971–1980,
2000.
[51] C. Gerhardinger, M. B. Costa, M. C. Coulombe, I. Toth, T.
Hoehn, and P. Grosu, “Expression of acute-phase response
proteins in retinal Müller cells in diabetes,” Investigative Oph-
thalmology & Visual Science, vol. 46, no. 1, pp. 349–357, 2005.
[52] E. Lieth, A. J. Barber, B. Xu et al., “Glial reactivity and impaired
glutamate metabolism in short- term experimental diabetic
retinopathy. Penn State Retina Research Group,” Diabetes, vol.
47, pp. 815–820, 1998.
[53] E. Lieth, K. F. LaNoue, D. A. Antonetti, and M. Ratz, “Diabetes
reduces glutamate oxidation and glutamine synthesis in the
retina. e Penn State Retina Research Group,” Experimental
Eye Research, vol. 70, no. 6, pp. 723–730, 2000.
[54] R. A. Kowluru, R. L. Engerman, G. L. Case, and T. S. Kern,
“Retinal glutamate in diabetes and effect of antioxidants,”
Neurochemistry International, vol. 38, no. 5, pp. 385–390, 2001.
[55] J. E. Pulido, J. S. Pulido, J. C. Erie et al., “A role for excitatory
amino acids in diabetic eye disease,” Experimental Diabesity
Research, vol. 2007, Article ID 36150, 7 pages, 2007.
[56] Y. K. Ng, X. X. Zeng, and E. A. Ling, “Expression of gluta-
mate receptors and calcium-binding proteins in the retina of
streptozotocin-induced diabetic rats,” Brain Research, vol. 1018,
no. 1, pp. 66–72, 2004.
[57] A. R. Santiago, J. M. Gaspar, F. I. Baptista et al., “Diabetes
changes the levels of ionotropic glutamate receptors in the rat
retina,”Molecular Vision, vol. 15, pp. 1620–1630, 2009.
[58] P. Aoun, J. W. Simpkins, and N. Agarwal, “Role of PPAR-𝛾𝛾 lig-
ands in neuroprotection against glutamate-induced cytotoxicity
in retinal ganglion cells,” Investigative Ophthalmology & Visual
Science, vol. 44, no. 7, pp. 2999–3004, 2003.
[59] A. Bernardo, G. Levi, and L. Minghetti, “Role of the peroxi-
some proliferator-activated receptor-𝛾𝛾 (PPAR-𝛾𝛾) and its natural
ligand 15-deoxy-Δ(12,14)-prostaglandin J2 in the regulation of
microglial functions,” European Journal of Neuroscience, vol. 12,
no. 7, pp. 2215–2223, 2000.
[60] A. Bernardo, M. A. Ajmone-Cat, L. Gasparini, E. Ongini,
and L. Minghetti, “Nuclear receptor peroxisome proliferator-
activated receptor-𝛾𝛾 is activated in rat microglial cells by the
anti-in�ammatory drugHCT1026, a derivative of �urbiprofen,”
Journal of Neurochemistry, vol. 92, no. 4, pp. 895–903, 2005.
[61] P. Li, X. Xu, Z. Zheng, B. Zhu, Y. Shi, and K. Liu, “Protective
effects of rosiglitazone on retinal neuronal damage in diabetic
rats,” Current Eye Research, vol. 36, no. 7, pp. 673–679, 2011.
[62] E. L. Fletcher, J. A. Phipps, M. M. Ward, K. A. Vessey, and J.
L. Wilkinson-Berka, “e renin-angiotensin system in retinal
health and disease: its in�uence on neurons, glia and the
vasculature,” Progress in Retinal and Eye Research, vol. 29, no.
4, pp. 284–311, 2010.
[63] S. Sarlos and J. L.Wilkinson-Berka, “e renin-angiotensin sys-
tem and the developing retinal vasculature,” Investigative Oph-
thalmology &Visual Science, vol. 46, no. 3, pp. 1069–1077, 2005.
[64] N. Nagai, K. Noda, T. Urano et al., “Selective suppression
of pathologic, but not physiologic, retinal neovascularization
by blocking the angiotensin II type 1 receptor,” Investigative
Ophthalmology & Visual Science, vol. 46, no. 3, pp. 1078–1084,
2005.
[65] M. Schupp, J. Janke, R. Clasen, T. Unger, and U. Kintscher, “An-
giotensin type 1 receptor blockers induce peroxisome prolifer-
ator-activated receptor-𝛾𝛾 activity,” Circulation, vol. 109, no. 17,
pp. 2054–2057, 2004.
[66] R. Simó, M. Villarroel, L. Corraliza, C. Hernández, and
M. Garcia-Ramírez, “e retinal pigment epithelium: some-
thing more than a constituent of the blood-retinal bar-
rier—implications for the pathogenesis of diabetic retinopathy,”
Journal of Biomedicine and Biotechnology, vol. 2010, Article ID
190724, 15 pages, 2010.
[67] A. V. Ershov and N. G. Bazan, “Photoreceptor phagocytosis
selectively activates PPARgamma expression in retinal pigment
epithelial cells,” Journal of Neuroscience Research, vol. 60, pp.
328–337, 2000.
[68] N. Toda and M. Nakanishi-Toda, “Nitric oxide: ocular blood
�ow, glaucoma, and diabetic retinopathy,” Progress in Retinal
and Eye Research, vol. 26, no. 3, pp. 205–238, 2007.
[69] A. Ergul, “Endothelin-1 and diabetic complications: focus on
the vasculature,” Pharmacological Research, vol. 63, no. 6, pp.
477–482, 2011.
[70] J. Kim, Y. S. Oh, and S. H. Shinn, “Troglitazone reverses the
inhibition of nitric oxide production by high glucose in cultured
bovine retinal pericytes,” Experimental Eye Research, vol. 81, no.
1, pp. 65–70, 2005.
[71] T. Omae, T. Nagaoka, I. Tanano, and A. Yoshida, “Pioglitazone,
a peroxisome proliferator-activated receptor-gamma agonist,
induces dilation of isolated porcine retinal arterioles: role of
nitric oxide and potassium channels,” Investigative Ophthalmol-
ogy & Visual Science, vol. 52, no. 9, pp. 6749–6756, 2011.
[72] H. Satoh, K. Tsukamoto, Y. Hashimoto et al., “iazolidine-
diones suppress endothelin-1 secretion from bovine vascular
endothelial cells: a new possible role of PPAR𝛾𝛾 on vascular
endothelial function,” Biochemical and Biophysical Research
Communications, vol. 254, no. 3, pp. 757–763, 1999.
[73] D. Ray, M. Mishra, S. Ralph, I. Read, R. Davies, and P.
Brenchley, “Association of the VEGF gene with proliferative
diabetic retinopathy but not proteinuria in diabetes,” Diabetes,
vol. 53, no. 3, pp. 861–864, 2004.
[74] M. Colucciello, “Vision loss due to macular edema induced by
rosiglitazone treatment of diabetes mellitus,” Archives of Oph-
thalmology, vol. 123, no. 9, pp. 1273–1275, 2005.
[75] E. H. Ryan Jr., D. P. Han, R. C. Ramsay et al., “Diabetic macular
edema associated with glitazone use,” Retina, vol. 26, no. 5, pp.
562–570, 2006.
[76] N. V. Niemeyer and L. M. Janney, “iazolidinedione-induced
edema,” Pharmacotherapy, vol. 22, no. 7, pp. 924–929, 2002.
[77] D. S. Fong and R. Contreras, “Glitazone use associated with
diabetic macular edema,” American Journal of Ophthalmology,
vol. 147, no. 4, pp. 583.e1–586.e1, 2009.
[78] I. Idris, G. Warren, and R. Donnelly, “Association between
thiazolidinedione treatment and risk of macular edema among
10 PPAR Research
patients with type 2 diabetes,”Archives of Internal Medicine, vol.
172, no. 13, pp. 1005–1011, 2012.
[79] W. T. Ambrosius, R. P. Danis, D. C. Goff Jr. et al., “Lack
of association between thiazolidinediones and macular edema
in type 2 diabetes: the ACCORD eye substudy,” Archives of
Ophthalmology, vol. 128, no. 3, pp. 312–318, 2010.
[80] M. Colucciello and E. Ryan, “Macular edema and thiazoli-
dinediones,” Archives of Ophthalmology, vol. 128, no. 12, pp.
1630–1631, 2010.
[81] K. Muranaka, Y. Yanagi, Y. Tamaki et al., “Effects of peroxisome
proliferator-activated receptor 𝛾𝛾 and its ligand on blood-
retinal barrier in a streptozotocin-induced diabetic model,”
Investigative Ophthalmology &Visual Science, vol. 47, no. 10, pp.
4547–4552, 2006.
[82] Z. Zheng, H. Chen, H. Wang et al., “Improvement of retinal
vascular injury in diabetic rats by statins is associated with the
inhibition of mitochondrial reactive oxygen species pathway
mediated by peroxisome proliferator-activated receptor 𝛾𝛾 coac-
tivator 1𝛼𝛼,” Diabetes, vol. 59, no. 9, pp. 2315–2325, 2010.
[83] D. K. Coletta, A. Sriwijitkamol, E. Wajcberg et al., “Pioglita-
zone stimulates AMP-activated protein kinase signalling and
increases the expression of genes involved in adiponectin
signalling, mitochondrial function and fat oxidation in human
skeletal muscle in vivo: a randomised trial,” Diabetologia, vol.
52, no. 4, pp. 723–732, 2009.
[84] K. Yamakawa, M. Hosoi, H. Koyama et al., “Peroxisome prolif-
erator-activated receptor-𝛾𝛾 agonists increase vascular endothe-
lial growth factor expression in human vascular smooth muscle
cells,” Biochemical and Biophysical Research Communications,
vol. 271, no. 3, pp. 571–574, 2000.
[85] M. Emoto, T. Anno, Y. Sato et al., “Troglitazone treatment
increases plasma vascular endothelial growth factor in diabetic
patients and its mRNA in 3T3-L1 adipocytes,”Diabetes, vol. 50,
no. 5, pp. 1166–1170, 2001.
[86] V. Chintalgattu, G. S. Harris, S. M. Akula, and L. C. Katwa,
“PPAR-𝛾𝛾 agonists induce the expression of VEGF and its
receptors in cultured cardiac myo�broblasts,” Cardiovascular
Research, vol. 74, no. 1, pp. 140–150, 2007.
[87] T. Murata, Y. Hata, T. Ishibashi et al., “Response of experimen-
tal retinal neovascularization to thiazolidinediones,”Archives of
Ophthalmology, vol. 119, no. 5, pp. 709–717, 2001.
[88] A. Aljada, L. O’Connor, Y. Y. Fu, and S. A. Mousa, “PPAR𝛾𝛾
ligands, rosiglitazone and pioglitazone, inhibit bFGF- and
VEGF-mediated angiogenesis,” Angiogenesis, vol. 11, no. 4, pp.
361–367, 2008.
[89] A. Higuchi, K. Ohashi, R. Shibata, S. Sono-Romanelli, K.Walsh,
andN. Ouchi, “iazolidinediones reduce pathological neovas-
cularization in ischemic retina via an adiponectin-dependent
mechanism,”Arteriosclerosis,rombosis, and Vascular Biology,
vol. 30, no. 1, pp. 46–53, 2010.
[90] G. A. Rodrigues, F. Maurier-Mahé, D. L. Shurland et al., “Dif-
ferential effects of PPAR𝛾𝛾 ligands on oxidative stress-induced
death of retinal pigmented epithelial cells,” Investigative Oph-
thalmology & Visual Science, vol. 52, no. 2, pp. 890–903, 2011.
[91] H. Hatanaka, N. Koizumi, N. Okumura et al., “Epithelial-
mesenchymal transition-like phenotypic changes of retinal
pigment epithelium induced by TGF-𝛽𝛽 are prevented by PPAR-
𝛾𝛾 agonists,” Investigative Ophthalmology & Visual Science, vol.
53, no. 11, pp. 6955–6963, 2012.
[92] L. Q. Shen, A. Child, G. M. Weber, J. Folkman, and L. P.
Aiello, “Rosiglitazone and delayed onset of proliferative dia-
betic retinopathy,” Archives of Ophthalmology, vol. 126, no. 6,
pp. 793–799, 2008.
[93] V. Pasceri, H. D. Wu, J. T. Willerson, and E. T. H. Yeh, “Modu-
lation of vascular in�ammation in vitro and in vivo by perox-
isome proliferator-activated receptor-𝛾𝛾 activators,” Circulation,
vol. 101, no. 3, pp. 235–238, 2000.
[94] M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass,
“e peroxisome proliferator-activated receptor-𝛾𝛾 is a negative
regulator of macrophage activation,” Nature, vol. 391, no. 6662,
pp. 79–82, 1998.
[95] H. Shu, B. Wong, G. Zhou et al., “Activation of PPAR𝛼𝛼 or
𝛾𝛾 reduces secretion of matrix metalloproteinase 9 but not
interleukin 8 from humanmonocytic THP-1 cells,” Biochemical
and Biophysical Research Communications, vol. 267, no. 1, pp.
345–349, 2000.
[96] T. Ishizuka, S. Itaya, H. Wada et al., “Differential effect of the
antidiabetic thiazolidinediones troglitazone and pioglitazone
on human platelet aggregation mechanism,” Diabetes, vol. 47,
no. 9, pp. 1494–1500, 1998.
[97] B. P. Harrold, V. J. Marmion, and K. R. Gough, “A double-
blind controlled trial of clo�brate in the treatment of diabetic
retinopathy,” Diabetes, vol. 18, no. 5, pp. 285–291, 1969.
[98] P. A. Dorne, “Exudative diabetic retinopathy. e use of clo�-
brate in the treatment of hard exudates using a reduced but pro-
longed dosage over several years,”Archives d’Ophtalmologie, vol.
37, no. 5, pp. 393–400, 1977.
[99] A. Keech, R. J. Simes, P. Barter et al., “Effects of long-term
feno�brate therapy on cardiovascular events in 9795 people
with type 2 diabetes mellitus (the FIELD study): randomised
controlled trial,”e Lancet, vol. 366, no. 9500, pp. 1849–1861,
2005.
[100] A. C. Keech, P. Mitchell, P. A. Summanen et al., “Effect
of feno�brate on the need for laser treatment for diabetic
retinopathy (FIELD study): a randomised controlled trial,”e
Lancet, vol. 370, no. 9600, pp. 1687–1697, 2007.
[101] E. Y. Chew, W. T. Ambrosius, M. D. Davis et al., “Effects
of medical therapies on retinopathy progression in type 2
diabetes,” e New England Journal of Medicine, vol. 363, no.
3, pp. 233–244, 2010.
[102] R. Sim� and C. Hernández, “Feno�brate for diabetic retinopa-
thy,”e Lancet, vol. 370, no. 9600, pp. 1667–1668, 2007.
[103] H. N. Ginsberg, M. B. Elam, L. C. Lovato et al., “Effects of
combination lipid therapy in type 2 diabetes mellitus,”e New
England Journal of Medicine, vol. 362, no. 17, pp. 1563–1574,
2010.
[104] M. García-Ramírez, F. Canals, C. Hernández et al., “Proteomic
analysis of human vitreous �uid by �uorescence-based differ-
ence gel electrophoresis (DIGE): a new strategy for identifying
potential candidates in the pathogenesis of proliferative diabetic
retinopathy,” Diabetologia, vol. 50, no. 6, pp. 1294–1303, 2007.
[105] R. Simo, M. Garcia-Ramirez, M. Higuera, and C. Hernandez,
“Apolipoprotein A1 is overexpressed in the retina of diabetic
patients,” American Journal of Ophthalmology, vol. 147, no. 2,
pp. 319.e1–325.e1, 2009.
[106] B. Staels, J. Dallongeville, J. Auwerx, K. Schoonjans, E. Leiters-
dorf, and J. C. Fruchart, “Mechanism of action of �brates on
lipid and lipoprotein metabolism,” Circulation, vol. 98, no. 19,
pp. 2088–2093, 1998.
[107] R. Arakawa, N. Tamehiro, T. Nishimaki-Mogami, K. Ueda, and
S. Yokoyama, “Feno�bric acid, an active form of feno�brate,
PPAR Research 11
increases apolipoprotein A-I-mediated high-density lipopro-
tein biogenesis by enhancing transcription of ATP-binding
cassette transporter A1 gene in a liver X receptor-dependent
manner,”Arteriosclerosis,rombosis, and Vascular Biology, vol.
25, no. 6, pp. 1193–1197, 2005.
[108] M. B. Sasongko, T. Y. Wong, T. T. Nguyen, J. E. Shaw,
A. J. Jenkins, and J. J. Wang, “Novel versus traditional risk
markers for diabetic retinopathy,” Diabetologia, vol. 55, no. 3,
pp. 666–670, 2012.
[109] R. Bordet, T. Ouk, O. Petrault et al., “PPAR: a new pharmaco-
logical target for neuroprotection in stroke and neurodegener-
ative diseases,” Biochemical Society Transactions, vol. 34, no. 6,
pp. 1341–1346, 2006.
[110] H. Murakami, R. Murakami, �. Kambe et al., “�eno�brate acti-
vates AMPK and increases eNOS phosphorylation in HUVEC,”
Biochemical and Biophysical Research Communications, vol.
341, no. 4, pp. 973–978, 2006.
[111] M. Zanetti, A. Stocca, B. Dapas et al., “Inhibitory effects
of feno�brate on apoptosis and cell proliferation in human
endothelial cells in high glucose,” Journal ofMolecularMedicine,
vol. 86, no. 2, pp. 185–195, 2008.
[112] A. Tomizawa, Y. Hattori, T. Inoue, S. Hattori, and K. Kasai,
“�eno�brate suppresses microvascular in�ammation and apop-
tosis through adenosinemonophosphate-activated protein kin-
ase activation,”Metabolism, vol. 60, no. 4, pp. 513–522, 2011.
[113] J. Kim, J. H. Ahn, J. H. Kim et al., “�eno�brate regulates retinal
endothelial cell survival through theAMPK signal transduction
pathway,”Experimental Eye Research, vol. 84, no. 5, pp. 886–893,
2007.
[114] S. Miranda, A. Gonzalez-Rodriguez, M. Garcia-Ramirez et al.,
“Bene�cial effects of feno�brate in retinal pigment epithelium
by the modulation of stress and survival signaling under
diabetic conditions,” Journal of Cellular Physiology, vol. 227, no.
6, pp. 2352–2362, 2012.
[115] D. A. Antonetti, R. Klein, and T. W. Gardner, “Diabetic
retinopathy,”eNew England Journal of Medicine, vol. 366, pp.
1227–1239, 2012.
[116] G. Chinetti, S. Griglio, M. Antonucci et al., “Activation of
proliferator-activated receptors 𝛼𝛼 and 𝛾𝛾 induces apoptosis of
humanmonocyte-derived macrophages,”e Journal of Biolog-
ical Chemistry, vol. 273, no. 40, pp. 25573–25580, 1998.
[117] Z. Israelian-Konaraki and P. D. Reaven, “Peroxisome prolif-
erator-activated receptor-alpha and atherosclerosis: from basic
mechanisms to clinical implications,” Cardiology, vol. 103, no.
1, pp. 1–9, 2005.
[118] M. Villarroel, M. Garcia-Ramirez, L. Corraliza, C. Hernandez,
and R. Simo, “�eno�bric acid prevents retinal pigment epithe-
lium disruption induced by interleukin-1beta by suppressing
AMP-activated protein kinase (AMPK) activation,” Diabetolo-
gia, vol. 54, no. 6, pp. 1543–1553, 2011.
[119] K. Trudeau, S. Roy, W. Guo et al., “�eno�bric acid reduces
�bronectin and collagen type IV overexpression in human
retinal pigment epithelial cells grown in conditions mimicking
the diabetic milieu: functional implications in retinal perme-
ability,” Investigative Ophthalmology & Visual Science, vol. 52,
pp. 6348–6354, 2011.
[120] I. Inoue, K. Shino, S. Noji, T. Awata, and S. Katayama,
“Expression of peroxisome proliferator-activated receptor 𝛼𝛼
(PPAR𝛼𝛼) in primary cultures of human vascular endothelial
cells,” Biochemical and Biophysical Research Communications,
vol. 246, no. 2, pp. 370–374, 1998.
[121] M. Meissner, M. Stein, C. Urbich et al., “PPAR𝛼𝛼 activators
inhibit vascular endothelial growth factor receptor-2 expression
by repressing Sp1-dependent DNA binding and transactiva-
tion,” Circulation Research, vol. 94, no. 3, pp. 324–332, 2004.
[122] J. Varet, L. Vincent, P. Mirshahi et al., “�eno�brate inhibits
angiogenesis in vitro and in vivo,” Cellular and Molecular Life
Sciences, vol. 60, no. 4, pp. 810–819, 2003.
[123] Y. Yokoyama, B. Xin, T. Shigeto et al., “Clo�bric acid, a perox-
isome proliferator-activated receptor 𝛼𝛼 ligand, inhibits growth
of human ovarian cancer,” Molecular Cancer erapeutics, vol.
6, no. 4, pp. 1379–1386, 2007.
[124] Y. Chen, Y. Hu, M. Lin et al., “erapeutic effects of PPARalpha
agonists on diabetic retinopathy in type 1 diabetes models,”
Diabetes, vol. 62, no. 1, pp. 261–272, 2013.
[125] R. L. Stephen, M. C. U. Gustafsson, M. Jarvis et al., “Activation
of peroxisome proliferator-activated receptor delta stimulates
the proliferation of human breast and prostate cancer cell lines,”
Cancer Research, vol. 64, no. 9, pp. 3162–3170, 2004.
